Literature DB >> 21910569

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

Ian S Zagon, Patricia J McLaughlin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910569     DOI: 10.1586/egh.11.62

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


× No keyword cloud information.
  5 in total

1.  Low-dose Naltrexone for the treatment of sarcoidosis.

Authors:  Leonard B Weinstock; Trisha L Myers; Anup Shetty
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats.

Authors:  Nahid Fakhraei; Nina Javadian; Reza Rahimian; Fatemeh Nili; Nastaran Rahimi; Shiva Hashemizadeh; Ahmad Reza Dehpour
Journal:  Inflammopharmacology       Date:  2018-10-15       Impact factor: 4.473

3.  Role of the δ-Opioid Receptor in 2 Murine Models of Colitis.

Authors:  Tia R Bobo; Leo R Fitzpatrick; Tiffany L Whitcomb; Timothy K Cooper; Sorana Raiciulescu; Jill P Smith
Journal:  Comp Med       Date:  2020-01-22       Impact factor: 0.982

Review 4.  Low dose naltrexone for induction of remission in Crohn's disease.

Authors:  Claire E Parker; Tran M Nguyen; Dan Segal; John K MacDonald; Nilesh Chande
Journal:  Cochrane Database Syst Rev       Date:  2018-04-01

5.  The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study.

Authors:  Guttorm Raknes; Pia Simonsen; Lars Småbrekke
Journal:  J Crohns Colitis       Date:  2018-05-25       Impact factor: 9.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.